Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 818 posts found.

Novartis’ Mayzent granted license by the European Medicines Agency

January 21, 2020
Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis

The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …

News
abbvie_0

AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance

January 16, 2020
Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …

News
novartis_window

Novartis’ ligelizumab tops Xolair in chronic spontaneous urticaria

January 9, 2020
Research and Development Novartis, Xolair, ligelizumab

Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair …

News
8266471202_63a8f743a9_b_0

Merck, Novartis and Allergan to raise US drug prices, following most of drug industry

January 6, 2020
Manufacturing and Production Allgeran, Big Pharma, Merck, Novartis, drug, drug prices

Following most of the large pharmaceutical companies, Merck, Novartis and Allergan have chosen to raise their drug prices. Novartis is …

News

Novartis plans giveaways of world’s most expensive drug

December 19, 2019
Business Services Novartis, Zolgensma, sma

Novartis plans to giveaway 50 doses of the world’s costliest single-dose treatment, Zolgensma, for babies under 2 years old, with …

News
novartis_outside_1

Novartis abandons asthma drug after Phase 3 trial results

December 17, 2019
Manufacturing and Production Novartis, Novartis. R&D, asthma, novartis r&d

Novartis have said it is not going forward with a new asthma drug, as the treatement failed its Phase 3 …

News

Novartis pulls fevipiprant development in asthma following trial failure

December 16, 2019
Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure

Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …

News
novartis_window

Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration

December 13, 2019
Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma

Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …

News

Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer

December 12, 2019
Business Services Journal of Medicine, Novartis, menopause

Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in …

News
novartis_gilenya_multiple_sclerosis_2

FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis

December 6, 2019
Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma

The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …

News

Amazon and Novartis team up on cloud services

December 5, 2019
Sales and Marketing Amazon Web Services, Cloud services, Novartis, amazon, pharma, product lines

Novartis is teaming up with Amazon Web Services to utilise its cloud computing technology. The collaboration is designed to overhaul …

News
34778112_496a002303_b

Drugmakers cut prices by 61% to get on Chinese reimbursement list

November 28, 2019
Manufacturing and Production AstraZeneca, China, China National Reimbursement Scheme, Novartis, Roche Holding

AstraZeneca and Roche Holding are among a number of drugmakers to cut their prices in order to get on China’s …

News
novartis_outside_1

Novartis acquires The Medicines Company in a deal worth $9.7 billion

November 25, 2019
Sales and Marketing Novartis, The Medicines Company, pharma

Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously …

News
mayzent

EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis

November 18, 2019
Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

News

Novartis’ Adakveo becomes first FDA-approved P-selectin inhibitor for sickle cell disease

November 18, 2019
Sales and Marketing Adakve, Novartis, pharma, sickle cell disease

The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …

News

Latest content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024